Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Makes more sense, I hope. This stock does the exact opposite of what you think it will do. I can;t help but think something positive is in the works. Although I have felt that numerous times before.
Is there any chance ADXS pushed Merck to shi* or get off the pot, instead of Merck just pulling out?
Any guesses on what's going on?
What's up with ADRO? They have been on a tear as of late.
Short lived rally....
She's running!!! lol
Like I said, F' em all and ill will to em all....They are in it for themselves and could care less about you or I..I hope for karma...
They've all f'd it up. f' em all!!!!
who said anything about wanting to destroy my investment...
If it were positive the SP would be trending up, not down...
Is there any reason to hold onto my shares any longer? I am concerned about a reverse split and am having trouble seeing any upside to this POS.
Finished strong..... :)
Who would buy the offering? What's the point?
I guess my question is, if there was a milestone payment due upon first dosing would it be something they would announce right away or is it something that would need to wait? And if the latter, why?
Shouldnt they receive a milestone from AMGN for first dosing? Wouldnt that seem practical? If so when would we hear about it?
I cant help but think they sat on getting this hold lifted, but why?
Hopefully all the bad news is now out. If that is the case we should be in good shape.
I came close to selling yesterday, let's turn this ship around!
Hold lifted, yahoo showing up 1.14 in pre-market?
Me want Sushi party...
How about the shorts are tired of no price action and are moving elsewhere?
Not sold on a reason to suppress the share price, care to share?
Why would there be a clause that prevents disclosing a milestone payment? What's the reasoning on Amgen's part?
What should we call your "buddy", he should have a name dont you think?
The PR appears to be another loser for ADXS. The information that is needed is never addressed. The milestone payment is the elephant in the room and they choose to not even acknowledge it. How about, "the first dosing will trigger a milestone payment per our agreement with AMGN with further details to follow" or "this first dosing puts us on target to reach our first milestone payment with AMGN later in the year". The PR was old news.
they were playing a game of chicken and lost...very clear what they were doing...
Thank god! She was useless.
Ok, bet is on!
I think we move over $2 today....
I think he will be the last CEO, one way or another...
the email program I use has a read receipt app installed...
I was just surprised at how quickly he opened the email....
I have sent two emails to Ken since he has been on board. He has opened both within minutes of receiving and replied to neither. He doesnt appear to be very busy to me.
I'm sure she is on vacation again....
No, its not worth their time, nor should it.
Any analyst who is using message boards as part of their research should not be an analyst...
I read 1.69 somewhere....
"The problem is that the context is quite complicated. To have a full grasp of the situation, you need to know every CRPC option, how many of those patients have failed, and you need to know every scrap of info known about pembro to date, which isn't that much. "
Therein lies the problem, the results, to be good, should not be complicated to comprehend....
In a Phase I trial with nivolumab, none of the 17 patients with metastatic CRPC experienced objective clinical responses;44 thus, the clinical development of targeting PD-1/PDL-1 as a monotherapy was curtailed. The lack of antitumor responses may be due to a paucity of PD-L1 expression in the prostate tumor microenvironment,45 as the expression of PD-L1 in tumor tissues has been associated with responsiveness to anti-PD-1/PD-L1 targeting.44,46 It should be noted that PD-L1 expression in the tumor microenvironment can be a dynamic process. When T cells enter the tumor, there is an upregulation of the immune checkpoints (e.g., CTLA-4 and PD-1), as well as the production of the cytokine, IFN-?, which leads to upregulation of PD-L1 within the tumor microenvironment.47 Therefore, therapies such as ipilimumab and sipuleucel-T,11,48,49 which induce T cell infiltration within the tumor, could be combined with agents targeting PD-1/PD-L1 to successfully treat advanced prostate cancer.
Seems par for the course...